Professor Quentin M. Anstee BSc(Hons), MB BS, PhD, MRCP(UK), FRCP
Professor of Experimental Hepatology & Honorary Consultant Hepatologist
Institute of Cellular Medicine, Newcastle University, U.K.
Professor Quentin Anstee is an Academic Hepatologist based in the Institute of Cellular Medicine, Newcastle University, UK. A practising clinician, he is also an Honorary Consultant Hepatologist in the Liver Transplant Unit at the Freeman Hospital, Newcastle. His particular specialist interest is the diagnosis and treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).
He trained in medicine at University College London where he was awarded First Prize in Medicine in the final MB BS examination (The Philip Seth Belasco & Douglas Cree Prize, 1997). His post-graduate specialist clinical training was undertaken in hospitals in North-West London. Prior to joining Newcastle in 2010, he worked as Clinical Lecturer in Medicine & Hepatology at Imperial College London and St Mary's Hospital.
His translational research focuses on the pathogenesis, risk stratification and treatment of NAFLD and in particular the study of genetic and epigenetic modifiers of progressive liver disease both in large, well phenotyped patient cohorts and through complementary laboratory approaches including gene-driven and phenotype‐driven ethyl-nitrosourea (ENU) mutagenesis and targeted genetic modification.
Prof Anstee is co-ordinator and principal investigator of the EU Horizon 2020 funded ‘EPoS’ Elucidating Pathways of Steatohepatitis consortium (2015-2019) and European NAFLD Registry. He oversaw the FP7 Fatty Liver Inhibition of Progression ' FLIP ' consortium genetic work package (2010-2013), led the IMPC/MRC UK Genetics of Liver Disease ‘UK GoLD’ consortium and co-founded the UK-NAFLD clinical research network. He was the recipient of a HEFCE Clinical Senior Lecturer Award, an MRC Clinical Research Fellowship and has received grant funding from the MRC, European Commission, Academy of Medical Sciences/Wellcome Trust and industrial partners.